Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10325461rdf:typepubmed:Citationlld:pubmed
pubmed-article:10325461lifeskim:mentionsumls-concept:C0376298lld:lifeskim
pubmed-article:10325461lifeskim:mentionsumls-concept:C0011615lld:lifeskim
pubmed-article:10325461lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:10325461lifeskim:mentionsumls-concept:C0023866lld:lifeskim
pubmed-article:10325461lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:10325461lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:10325461pubmed:issue2lld:pubmed
pubmed-article:10325461pubmed:dateCreated1999-6-16lld:pubmed
pubmed-article:10325461pubmed:abstractTextThis paper reflects the consensus reached among Belgian professors of dermatology on the place of cyclosporin (CsA) in the treatment of atopic dermatitis (AD). Existing therapeutic modalities and ways to evaluate efficacy of treatment are reviewed briefly. Based on data from the literature and personal experience, guidelines for the use of CsA in AD are proposed. CsA can be prescribed in recalcitrant cases of AD on a short-term basis, both in adults and children. Long-term treatment, up to 1 year, should be considered only in exceptional cases that cannot be controlled by short-time therapy. Contraindications, drug interactions and necessary controls during treatment are also discussed.lld:pubmed
pubmed-article:10325461pubmed:languageenglld:pubmed
pubmed-article:10325461pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10325461pubmed:citationSubsetIMlld:pubmed
pubmed-article:10325461pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10325461pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10325461pubmed:statusMEDLINElld:pubmed
pubmed-article:10325461pubmed:issn1018-8665lld:pubmed
pubmed-article:10325461pubmed:authorpubmed-author:LambertJJlld:pubmed
pubmed-article:10325461pubmed:authorpubmed-author:LachapelleJ...lld:pubmed
pubmed-article:10325461pubmed:authorpubmed-author:de la...lld:pubmed
pubmed-article:10325461pubmed:authorpubmed-author:DegreefHHlld:pubmed
pubmed-article:10325461pubmed:authorpubmed-author:HeenenMMlld:pubmed
pubmed-article:10325461pubmed:authorpubmed-author:NaeyaertJ MJMlld:pubmed
pubmed-article:10325461pubmed:issnTypePrintlld:pubmed
pubmed-article:10325461pubmed:volume198lld:pubmed
pubmed-article:10325461pubmed:ownerNLMlld:pubmed
pubmed-article:10325461pubmed:authorsCompleteYlld:pubmed
pubmed-article:10325461pubmed:pagination145-52lld:pubmed
pubmed-article:10325461pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:10325461pubmed:meshHeadingpubmed-meshheading:10325461...lld:pubmed
pubmed-article:10325461pubmed:meshHeadingpubmed-meshheading:10325461...lld:pubmed
pubmed-article:10325461pubmed:meshHeadingpubmed-meshheading:10325461...lld:pubmed
pubmed-article:10325461pubmed:meshHeadingpubmed-meshheading:10325461...lld:pubmed
pubmed-article:10325461pubmed:year1999lld:pubmed
pubmed-article:10325461pubmed:articleTitleCyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus.lld:pubmed
pubmed-article:10325461pubmed:affiliationDepartment of Dermatology, University of Gent, Belgium. Dermatology@uzdermis.rug.ac.belld:pubmed
pubmed-article:10325461pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10325461pubmed:publicationTypeReviewlld:pubmed